First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression or histology
16499
post-template-default,single,single-post,postid-16499,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression or histology

Home > Blogs  > First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression or histology

23 Sep First-line cemiplimab prolongs advanced NSCLC survival irrespective of PD-L1 expression or histology

Posted at 10:30h in Blogs by

In patients with advanced NSCLC without EGFR, ALK, or ROS1 genomic tumor aberrations, treatment with cemiplimab plus chemotherapy showed a consistent relationship between ORR and baseline PD-L1 expression, with benefits versus chemotherapy alone seen across all levels of baseline PD-L1 expression; there was also a clear association between a continuous measure of changes in tumor size over time and baseline PD-L1 expression. Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in advanced NSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies. (Ref: Gogishvili M et al. Nat Med. Aug 25, 2022)
#oncologyresearch #clinicalresearch #clinicaldevelopment
https://www.linkedin.com/feed/update/urn:li:activity:6978947347456094208
No Comments

Sorry, the comment form is closed at this time.